The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge ...

A group of clinicians and patients has called on the government at Holyrood to adopt a “Scotland-wide focus” on chronic kidney disease (CKD), saying that as many as 600,000 Scots are now thought to be ...

AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an insurance ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca (GB:AZN) has released an update. AstraZeneca remains committed to delivering its innovative medicines in China despite ongoing ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

Good morning, everyone, and welcome to the Cellectis Third Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session ...

AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior ...

Mankia received grant support from Gilead, Lilly, AstraZeneca, and Serac Life Sciences and honoraria or consultant fees from AbbVie, UCB, Lilly, Galapagos, DeepCure, Serac Life Sciences, AstraZeneca, ...

Astrazeneca (AZN) closed at $71.42 in the latest trading session, marking a +0.38% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.41%. On the other hand, the ...